Evidence map›Paper›PMID 28391288›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2017

CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).

Yongfang Jiang, Ping Xu, Dandan Yao, Xi Chen, Haibin Dai

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. CD155: A Multi-Functional Molecule in Tumor Progression.International journal of molecular sciences · 2020
    Review
  10. Review
  11. Cluster of Differentiation 96 in Children with Acute Leukemia: A Single Center Cohort Study.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yongfang JiangDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Ping XuDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Dandan YaoDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Xi ChenDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Haibin DaiDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Second Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Leukemia stem cells (LSC) are involved in the incidence, drug resistance, and relapse of leukemia while LSC-related antigen CD33, CD96, and DAPK expression in AML and its prognosis is still unclear. This study explored LSC-related antigens expression in acute myeloid leukemia (AML) and its prognosis. MATERIAL AND METHODS A total of 156 cases of AML patients were enrolled in the experiment. The expression of CD33, CD96, and DAPK in CD34+CD38-CD123+ LSC were tested by flow cytometry. The survival curve was established using the Kaplan-Meier method. RESULTS Among different subtypes of AML, the positive rate of CD33 was M3> M5> M1> M2> M4; for CD96 it was M5> M4> M2> M3> M1; and for DAPK it was M3> M2> M5> M4> M1. After chemotherapy, the response rate in CD33 and CD96 high expression groups, and DAPK low expression group was significantly lower than the groups with CD33 low expression, CD96 low expression, and DAPK high expression. The median survival time in the CD33 high expression group was markedly lower than the CD33 low expression group (36.5 months). The CD96 high expression group exhibited obviously shorter median survival time than the CD96 low expression group. The DAPK high expression group exhibited longer median survival time than the DAPK low expression group. CONCLUSIONS CD33 and CD96 overexpression, and DAPK downregulation in the LSC of AML patients were associated with poor chemotherapy effect and prognosis, and higher recurrence rate.

Indexed as

AdolescentAdultAntigens, CDBiomarkers, PharmacologicalBone Marrow CellsDeath-Associated Protein KinasesFemaleFlow CytometryGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplastic Stem CellsPrognosisADGRE5 protein, humanAntigens, CDBiomarkers, PharmacologicalCD33 protein, humanDeath-Associated Protein KinasesReceptors, G-Protein-CoupledSialic Acid Binding Ig-like Lectin 3

Identifiers

PMID28391288
PMCPMC5395139
OpenAlexW2604540409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.